SCHEMBL24760182

SCHEMBL24760182

CC(C)(C)[Si](C)(C)O[C@@H]1CCN(Cc2ccccc2)C[C@H]1CO

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 2/20 0.45
ACHE P22303 2/20 0.42
ALDH1A1 P00352 2/20 0.41
SIGMAR1 Q99720 1/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
MCHR1 Q99705 1/20 0.40
BCHE P06276 1/20 0.40
BACE1 P56817 1/20 0.40
LMNA P02545 1/20 0.39
ALOX12 P18054 1/20 0.39
MAPK1 P28482 1/20 0.39
CYP2D6 P10635 1/20 0.39
DRD2 P14416 1/20 0.39
DRD4 P21917 1/20 0.39
DRD3 P35462 1/20 0.39
CHRM2 P08172 1/20 0.39
CHRM1 P11229 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24759936 1.00 GBA1 (0.45) GBA1ACHEALDH1A1SIGMAR1MEN1
SCHEMBL1869069 0.87 ACHE (0.41) ACHEALDH1A1MEN1KMT2ABCHE
SCHEMBL30994620 0.85 ACHE (0.43) ACHEALDH1A1BCHEBACE1CYP2D6
SCHEMBL15710626 0.84 ACHE (0.48) ACHEALDH1A1MEN1KMT2ABCHE
SCHEMBL15710627 0.84 ACHE (0.48) ACHEALDH1A1MEN1KMT2ABCHE
SCHEMBL24760631 0.84 ABL1 (0.41) GBA1ACHEALDH1A1MEN1KMT2A
SCHEMBL3620125 0.83 S1PR5 (0.43) ACHEALDH1A1MEN1KMT2AMCHR1
SCHEMBL3620120 0.83 S1PR5 (0.43) ACHEALDH1A1MEN1KMT2AMCHR1
SCHEMBL29198351 0.83 S1PR5 (0.43) ACHEALDH1A1MEN1KMT2AMCHR1
SCHEMBL29198366 0.83 S1PR5 (0.43) ACHEALDH1A1MEN1KMT2AMCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3806853-B1 COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES ONCO3R THERAPEUTICS BV (BE) 2026-03-18 EP disclosed
US-12264156-B2 Compounds and pharmaceutical compositions thereof for the treatment of diseases GALAPAGOS NV (BE) 2025-04-01 US disclosed
US-20220402911-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES GALAPAGOS NV (BE) 2022-12-22 US disclosed
US-20220402911-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES GALAPAGOS NV (BE) 2022-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220402911-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES IL1A, TNF, IL6 GBA1 402/4885ACHE 4638/4885ALDH1A1 1156/4885
US-12264156-B2 Compounds and pharmaceutical compositions thereof for the treatment of diseases TNF, IL1A, COL1A1 GBA1 474/4885ACHE 4546/4885ALDH1A1 1150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.